847-P: Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters across the Type 2 Diabetes Mellitus Disease Spectrum

847-P: Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters across the Type 2 Diabetes Mellitus Disease Spectrum

Introduction: HTD1801 is a gut-liver anti-inflammatory metabolic modulator shown to improve key glycemic and cardiometabolic parameters. The aim of this study was to evaluate the effectiveness of HTD1801 across the T2DM disease spectrum. Method: In a Ph2 study of treatment-naïve patients with T2DM 1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73, p.1
Hauptverfasser: Ji, Linong, Ma, Jianhua, Ma, Yujin, Cheng, Zhifeng, Gan, Shenglian, Yuan, Guoyue, Liu, Dexue, Li, Sheli, Liu, Yu, Xue, Xia, Bai, Jie, Wang, Kun, Cai, Hanqing, Li, Shu, Liu, Kui, Yu, Meng, Liu, Liping
Format: Artikel
Sprache:eng
Schlagworte:
Berberine
Diabetes mellitus (non-insulin dependent)
Liver diseases
Placebos
Risk groups
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: HTD1801 is a gut-liver anti-inflammatory metabolic modulator shown to improve key glycemic and cardiometabolic parameters. The aim of this study was to evaluate the effectiveness of HTD1801 across the T2DM disease spectrum. Method: In a Ph2 study of treatment-naïve patients with T2DM 113 patients were randomized 1:1:1 to placebo (n=38), HTD1801 500 mg BID (n=37), and 1000 mg BID (n=38) for 12 weeks. Key inclusion criteria included T2DM (WHO criteria), HbA1c 7%-10.5% and FPG
ISSN:0012-1797
1939-327X
DOI:10.2337/db24-847-P